Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T14687 |
Deucravacitinib
BMS-986165 |
Tyrosine Kinases; JAK; IFNAR; Interleukin | Angiogenesis; Chromatin/Epigenetic; Immunology/Inflammation; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Deucravacitinib (BMS-986165) 是一种高选择性、口服生物可利用的变构 TYK2 抑制剂,用于治疗自身免疫性疾病。它通过稳定调节 JH2 结构域来阻断受体介导的 Tyk2 激活,可抑制IL-12/23和 I 型IFN 途径。它选择性结合 TYK2 假激酶 (JH2) 结构域,IC50为1.0 nM。 | |||
T70393 |
PF-303
|
||
PF-303 is a covalent-reversible BTK inhibitor. Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for the treatment of oncologic and autoimmune indications. |